CD4+血细胞计数和HIV病毒载量对HIV和HCV合并感染患者直接抗病毒药物治疗反应的影响:来自德国丙型肝炎登记处的见解

Q2 Medicine
Jenny Bischoff, Stefan Mauss, Christiane Cordes, Thomas Lutz, Stefan Scholten, Markus Cornberg, Michael P Manns, Axel Baumgarten, Jürgen K Rockstroh
{"title":"CD4+血细胞计数和HIV病毒载量对HIV和HCV合并感染患者直接抗病毒药物治疗反应的影响:来自德国丙型肝炎登记处的见解","authors":"Jenny Bischoff,&nbsp;Stefan Mauss,&nbsp;Christiane Cordes,&nbsp;Thomas Lutz,&nbsp;Stefan Scholten,&nbsp;Markus Cornberg,&nbsp;Michael P Manns,&nbsp;Axel Baumgarten,&nbsp;Jürgen K Rockstroh","doi":"10.1080/15284336.2018.1538193","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Direct-acting antivirals (DAAs) lead to high cure rates of Hepatitis C Virus (HCV) infections in HIV/HCV coinfected patients. Recent data suggest that treatment failures occur more often in HIV/HCV coinfected persons.</p><p><strong>Objective: </strong>We aimed to identify risk factors for treatment failure in coinfected patients.</p><p><strong>Methods: </strong>We analyzed data collected from the German Hepatitis C-Registry (DHC-R, Trials Registration number DRKS00009717). 437 HIV/HCV coinfected patients were included. Sustained virological response (SVR) rates and the impact of CD4+ count, HIV viral load, liver cirrhosis and splenomegaly were evaluated.</p><p><strong>Results: </strong>83.5% (365/437) of the patients were male (average age: 46.6 ± 9.2 y). Most patients received antiretroviral therapy (ART) (88.1%; 385/437), had a HIV RNA ≤40 copies/ml (88.5%; 285/322) and were infected with HCV genotype (GT) 1 (77.6%; 339/437). Overall SVR12 rate was 92% (402/437). In patients with HIV RNA ≤40 copies/ml and >40 copies/ml SVR12 rates were 93.2% (272/292) and 85.3%, respectively (29/34; p = .11). SVR12 rates were 91.8% (45/49) and 92.7% (253/273; p = .84) in patients with a CD4+ <350/µl and ≥350/µl. We observed no difference in either of the subgroups in patients with cirrhosis or splenomegaly. In the univariate logistic regression analysis none of the analyzed HIV or HCV specific parameters, liver cirrhosis or splenomegaly were associated with treatment outcome.</p><p><strong>Conclusion: </strong>We found high SVR12 rates in HIV/HCV coinfected patients and no significant difference was observed due to the patients CD4+ cell count, HIV viral load, portal hypertension or liver cirrhosis.</p>","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/15284336.2018.1538193","citationCount":"1","resultStr":"{\"title\":\"Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.\",\"authors\":\"Jenny Bischoff,&nbsp;Stefan Mauss,&nbsp;Christiane Cordes,&nbsp;Thomas Lutz,&nbsp;Stefan Scholten,&nbsp;Markus Cornberg,&nbsp;Michael P Manns,&nbsp;Axel Baumgarten,&nbsp;Jürgen K Rockstroh\",\"doi\":\"10.1080/15284336.2018.1538193\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Direct-acting antivirals (DAAs) lead to high cure rates of Hepatitis C Virus (HCV) infections in HIV/HCV coinfected patients. Recent data suggest that treatment failures occur more often in HIV/HCV coinfected persons.</p><p><strong>Objective: </strong>We aimed to identify risk factors for treatment failure in coinfected patients.</p><p><strong>Methods: </strong>We analyzed data collected from the German Hepatitis C-Registry (DHC-R, Trials Registration number DRKS00009717). 437 HIV/HCV coinfected patients were included. Sustained virological response (SVR) rates and the impact of CD4+ count, HIV viral load, liver cirrhosis and splenomegaly were evaluated.</p><p><strong>Results: </strong>83.5% (365/437) of the patients were male (average age: 46.6 ± 9.2 y). Most patients received antiretroviral therapy (ART) (88.1%; 385/437), had a HIV RNA ≤40 copies/ml (88.5%; 285/322) and were infected with HCV genotype (GT) 1 (77.6%; 339/437). Overall SVR12 rate was 92% (402/437). In patients with HIV RNA ≤40 copies/ml and >40 copies/ml SVR12 rates were 93.2% (272/292) and 85.3%, respectively (29/34; p = .11). SVR12 rates were 91.8% (45/49) and 92.7% (253/273; p = .84) in patients with a CD4+ <350/µl and ≥350/µl. We observed no difference in either of the subgroups in patients with cirrhosis or splenomegaly. In the univariate logistic regression analysis none of the analyzed HIV or HCV specific parameters, liver cirrhosis or splenomegaly were associated with treatment outcome.</p><p><strong>Conclusion: </strong>We found high SVR12 rates in HIV/HCV coinfected patients and no significant difference was observed due to the patients CD4+ cell count, HIV viral load, portal hypertension or liver cirrhosis.</p>\",\"PeriodicalId\":13216,\"journal\":{\"name\":\"HIV Clinical Trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/15284336.2018.1538193\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Clinical Trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15284336.2018.1538193\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15284336.2018.1538193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

背景:直接作用抗病毒药物(DAAs)导致HIV/HCV合并感染患者丙型肝炎病毒(HCV)感染的高治愈率。最近的数据表明,治疗失败在艾滋病毒/丙型肝炎病毒合并感染者中更为常见。目的:我们旨在确定合并感染患者治疗失败的危险因素。方法:我们分析了从德国丙型肝炎登记处(DHC-R,试验注册号DRKS00009717)收集的数据。纳入437例HIV/HCV合并感染患者。评估持续病毒学反应(SVR)率以及CD4+计数、HIV病毒载量、肝硬化和脾肿大的影响。结果:83.5%(365/437)的患者为男性,平均年龄46.6±9.2 y,接受抗逆转录病毒治疗(ART)的患者占88.1%;385/437), HIV RNA≤40拷贝/ml (88.5%;285/322),感染HCV基因型(GT) 1 (77.6%;339/437)。总体SVR12率为92%(402/437)。在HIV RNA≤40拷贝/ml和>40拷贝/ml的患者中,SVR12的发生率分别为93.2%(272/292)和85.3% (29/34;p = .11)。SVR12阳性率分别为91.8%(45/49)和92.7% (253/273);结论:我们发现HIV/HCV合并感染患者的SVR12发生率较高,且CD4+细胞计数、HIV病毒载量、门静脉高压或肝硬化对SVR12发生率无显著影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

Background: Direct-acting antivirals (DAAs) lead to high cure rates of Hepatitis C Virus (HCV) infections in HIV/HCV coinfected patients. Recent data suggest that treatment failures occur more often in HIV/HCV coinfected persons.

Objective: We aimed to identify risk factors for treatment failure in coinfected patients.

Methods: We analyzed data collected from the German Hepatitis C-Registry (DHC-R, Trials Registration number DRKS00009717). 437 HIV/HCV coinfected patients were included. Sustained virological response (SVR) rates and the impact of CD4+ count, HIV viral load, liver cirrhosis and splenomegaly were evaluated.

Results: 83.5% (365/437) of the patients were male (average age: 46.6 ± 9.2 y). Most patients received antiretroviral therapy (ART) (88.1%; 385/437), had a HIV RNA ≤40 copies/ml (88.5%; 285/322) and were infected with HCV genotype (GT) 1 (77.6%; 339/437). Overall SVR12 rate was 92% (402/437). In patients with HIV RNA ≤40 copies/ml and >40 copies/ml SVR12 rates were 93.2% (272/292) and 85.3%, respectively (29/34; p = .11). SVR12 rates were 91.8% (45/49) and 92.7% (253/273; p = .84) in patients with a CD4+ <350/µl and ≥350/µl. We observed no difference in either of the subgroups in patients with cirrhosis or splenomegaly. In the univariate logistic regression analysis none of the analyzed HIV or HCV specific parameters, liver cirrhosis or splenomegaly were associated with treatment outcome.

Conclusion: We found high SVR12 rates in HIV/HCV coinfected patients and no significant difference was observed due to the patients CD4+ cell count, HIV viral load, portal hypertension or liver cirrhosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HIV Clinical Trials
HIV Clinical Trials 医学-传染病学
CiteScore
1.76
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信